INTRODUCTION
Patients with cancer who become granulocytopenic as a result of intensive myelosuppressive chemotherapy are at high risk of developing infections, 1 which may be lethal if empiric antibiotic treatment is not promptly instituted. Nowadays, single-agent empiric antibacterial therapy may be considered the standard of treatment. [1] [2] [3] Over the past 30 years, there has been a continuous change in the epidemiology of bacterial infections in neutropenic patients with cancer. Although Gram-positive cocci still represent the source of over 60% of bacteremias, [4] [5] [6] a new emergence of gram negatives has occurred, and the diffusion of multidrug resistant (MDR) microorganisms has been observed. [6] [7] [8] [9] [10] [11] These new epidemiologic settings in neutropenic patients with cancer may be responsible for the inadequacy of the commonly used empiric monotherapy regimens, 12, 13 which has led to an increased mortality.
14,15 New antiGram-positive drugs are currently available, but there are only a few therapeutic options for MDR Gramnegative infections. Tigecycline, the first in a new class of glycylcyclines, is characterized by a broad antibacterial spectrum that covers the majority of MDR Grampositive and Gram-negative strains, with the exclusion of Pseudomonas aeruginosa and Proteeae. [16] [17] [18] [19] [20] [21] Few clinical data on the safety and effectiveness of tigecycline in neutropenic patients with cancer are available. 22 To investigate the possible benefits resulting from the combination of this drug with the currently used monotherapy regimens, we have conducted a large, controlled randomized clinical trial by using piperacillin/tazobactam with or without tigecycline as empirical antibiotic therapy in febrile neutropenic adult patients with hematologic malignancies.
PATIENTS AND METHODS

Study Design and Participants
The study was a prospective, multicenter, unblinded, randomized, controlled, superiority trial planned, conducted, and analyzed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program. It was registered in the EU Clinical Trials Database and approved by the ethics committee at each participating center. The study was conducted between May 3, 2008 , and November 4, 2010, at 28 centers in Italy. Written informed consent was obtained from each patient.
Consecutive adult patients with hematologic malignancies undergoing intensive chemotherapy or conditioning regimens for autologous hematopoietic stem-cell transplantation were eligible to be randomly assigned if they had fever (Ն 38.5°C on one occasion or Ն 38°C on two or more occasions within 12 hours), chemotherapy-induced neutropenia (absolute neutrophils count Ͻ 1,000 per cubic millimeter anticipated to decrease to fewer than 500 cells per cubic millimeter within 24 to 48 hours), and a presumed infection (ie, fever not likely to be due to a noninfectious cause such as drug or blood product administration). Patients were enrolled only once in the study. Patients were excluded if they had received any intravenous antibiotics during the preceding 96 hours. Additional exclusion criteria are provided in the Appendix (online only). Quinolones prophylaxis was discontinued at randomization.
Trial Objectives
The primary objective of the study was to show superiority in the rates of successful response (defined as resolution of fever and clinical signs of infection and eradication of the infecting microorganisms, without modifications of the initial allocated treatment) of the combination over the monotherapy regimen. A response was defined as a failure if the patient died as a result of the primary infection; if bacteremia persisted beyond the first 24 hours of therapy; if a breakthrough bacteremia occurred; if the isolated pathogen was resistant to the assigned antibiotics; if no response was seen after at least 72 hours of therapy; if shock or acute respiratory distress syndrome or disseminated intravascular coagulation or multiple organ failure was observed; if infection relapsed within 7 days of treatment discontinuation; and if a toxicity attributed to protocol antibiotics that required the interruption of treatment occurred. Secondary end points were safety and tolerability. Survival at day 30 was also evaluated.
Clinical and Microbiologic Assessment, Follow-Up
Details on baseline and follow-up assessments are provided in the Appendix. Patients were evaluated for response at day 4 after empirical therapy initiation (early evaluation) and at the completion of the trial (overall evaluation). Standardized efforts to evaluate persistent or relapsing fever were made. Infections were classified according to the definitions of the European Organization for Research and Treatment of Cancer. The trial enrollment was stopped shortly before reaching the planned number (190) in this arm of the study because of impending expiry of the study insurance contract. However, after having consulted the central ethical committee, considering the large and conservative anticipated rate of not evaluability assumed in the sample size calculation, the data review committee was confident that an adequate number of evaluable patients would have been reached in each group of treatment, as it actually occurred.
Isolates identification and their susceptibility to antibiotics were evaluated at each participating center according to the Clinical and Laboratory Standards Institute guidelines. 24 The growth of coagulase-negative staphylococci (CNS) was considered as bacteremia when two or more blood cultures, drawn in separate occasions within 24 hours, yielded the same microorganism. Extended spectrum beta-lactamase production in Enterobacteriaceae was routinely carried out in three large centers. The minimum inhibitory concentration (MIC) for tigecycline was determined by using Etest (AB-BioMérieux, Solna, Sweden), and the MIC breakpoints for susceptibility issued by the European Committee on Antimicrobial Susceptibility Testing (Յ 1 mg/L) were used. 25 
Study Drug Treatment
At the onset of fever, patients were randomly assigned to receive piperacillin/tazobactam (4.5 g intravenously every 8 hours) with or without tigecycline (50 mg intravenously every 12 hours, loading dose of 100 mg) as empiric therapy. Antibiotic treatment was continued until success or failure was decided. The assigned therapy could be modified before day 4 only in the case of a worsening of the patient's clinical condition or if the isolated pathogen was resistant to the assigned antibiotics, otherwise the modification was considered a protocol violation.
Randomization and Statistical Analysis
Patients were centrally randomly assigned by using an automated computer randomization procedure. The randomization list was created by using a computer random generator program (Epistat, version 2) and was stratified by center and underlying disease with a 1:1 allocation by using a block size of eight. Participating centers were not aware of block size (Appendix).
According to our previous study, 12 we assumed that a favorable response would occur in approximately 50% of patients empirically treated with a piperacillin/tazobactam monotherapy regimen. We estimated that at least 340 patients (170 in each group) would be needed to detect an absolute difference of at least 15% between monotherapy and the combination regimen, with a statistical power of 80% and a 5% significance level. Anticipating a 10% nonevaluability rate, we planned to include at least 380 patients (190 in each group) in the trial.
All case report forms were centrally reviewed by the data review committee and entered into the computer system blinded for the assigned regimen. Statistical analyses were carried out at the Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program Data Center with the use of the SPSS software package (SPSS, Chicago, IL) and were made in a blinded fashion with respect to the assigned treatment. An analysis that included all eligible patients was deemed according to the intention to treat by considering that treatment was considered as failed in patients in whom response could not be assessed because they were lost to follow-up. A per-protocol analysis that included all assessable patients was conducted. Efficacy with respect to the primary and secondary end points was expressed as the absolute difference in rates between treatment groups (combination minus monotherapy regimen). The 95% CI for the difference between proportions was given. The 2 test with a correction for continuity or Fisher's exact test for small samples when necessary was used to compare proportions. The Wilcoxon rank sum test was used to compare continuous variables. A backward stepwise logistic regression model was used to assess the relative importance of the various prognostic factors assessable at the time of randomization.
RESULTS
A total of 390 febrile neutropenic hematologic patients with cancer were enrolled: 187 assigned to receive intravenous piperacillin/ tazobactam plus tigecycline; 203 intravenous piperacillin/tazobactam. The enrolment and outcome are shown in Figure 1 . The characteristics of patients included onto the study are provided in Table 1 .
Response to Therapy
The rates and the absolute differences in the risk (adr) of primary and secondary end points are shown in Figure 2 . An intention-to-treat analysis performed on the 390 eligible patients revealed that a successful outcome was obtained in 67.9% of patients in the combination group, compared with 44.3% of patients in the monotherapy group (P Ͻ .001).
A per-protocol analysis of patients whose response to the assigned treatment could be assessed yielded similar results. The response rate of microbiologically documented infections was significantly higher in the combination group than in the monotherapy treated patients (61.4% v 28.1%; P ϭ .001).
Overall, 97.8% (180 of 184) of the microbiologically documented infections were bacteremias (Fig 2) . The distribution of bacteremias, as well as the type of isolated pathogens, was similar in both treatment groups, with CNS and Escherichia coli being the most frequent isolates. CNS blood isolates were methicillin-resistant in 79.5% of cases. The prevalence of ESBL-producing strains documented by the three centers that routinely performed the screening and considered as representative sample accounted for 30% of Enterobacteriaceae.
The success rate of patients with bacteremia treated with the combination was 60.5%, compared with 27.7% of those treated with monotherapy (P Ͻ .001). Significantly higher success rates were observed in patients with CNS and E coli bacteremia (Fig 2) .
The reasons for failure are shown in Table 2 . Failure because of an isolate resistant to the initial allocated regimen occurred in eight of 174 patients treated with combination therapy (4.6%) compared with 27 of 190 patients treated with monotherapy (14.2%) (adr, Ϫ0.09; 95% CI, Ϫ0.15 to Ϫ0.03; P ϭ .001). Susceptibilities of single agents and polymicrobial bacteremias isolates are shown in Table 3 . Resistant pathogens were equally distributed in the two treatment groups. No differences were detected in the number of days to defervescence that were two (median, range 1 to 10) and three (median, range 1 to 17) in patients treated with combination therapy and monotherapy, respectively. The time to failure values were similar in both groups with a median number of days to failure of 4 (range, 1 to 13 for combination therapy and 1 to 17 for monotherapy).
Modification of the Allocated Antibiotic Regimen
Data on antibiotics prescribed as second-line treatment were available for 91% of cases of failure. A carbapenem (alone or in combination) replaced the first-line regimen in 72.8% (99 of 136) of failed cases, but overall 27.1% (99 of 364) of the assessable population received a carbapenem. The use of an antipseudomonal cephalosporin or a carbapenem was significantly higher in the monotherapy than in the combination regimen (67 of 183, 36.6% v 37 of 169, 21.9%; adr, 0.14; 95% CI, 0.05 to 0.24; P Ͻ .01). Similarly an anti-Gram-positive agent was used as second-line treatment in 69 of 183 (37.7%) and 25 of 169 (14.8%) of cases, respectively, in the monotherapy and in the combination regimen (adr, 0.23; 95% CI, 0.14 to 0.31; P Ͻ .01). Tigecycline was used as second-line therapy in 34 of 100 patients who failed on piperacillin/tazobactam monotherapy. In the 26 assessable cases, the success rate was 69% in 16 bacteremias and in three clinically documented infections, and it was 86% in seven cases of unexplained fever.
Multivariable Analysis
To estimate predictive factors that could influence the failure of empiric therapy, data from all assessable patients were fitted within a multivariable logistic regression model. Factors included in the model were as follows: antibiotic regimen, sex, age, performance status (WHO five-degree scale), underlying disease, neutrophil count at onset of fever, and duration of neutropenia. Although the duration of neutropenia Ն 10 days, acute leukemia, and monotherapy were significant factors for failure at the univariable level, only the last two resulted independent risk factors at the multivariable level (Table 4) .
Mortality
The mortality rates and causes of death were equally distributed between the two treatment groups (Table 5) . Overall, 16 patients (8.5%) who were in the combination group died, compared with 15 (7.3%) in the monotherapy group (P ϭ .4). Eleven patients died as a result of infectious causes in both treatment groups. Overall, 16 deaths were bacteremia related, and in 11 cases (68.7%) a Gram-negative microorganism was involved.
The bacteremia-related mortality rates were similar, being 4% in both regimens (P ϭ .4). Early death (within 72 hours from the start of the empiric therapy) in bacteremic febrile episodes occurred in one of 187 patients (0.5%) treated with combination regimen and in four of 203 patients (2%) treated with monotherapy (P ϭ .2; estimated relative risk, 0.27; 95% CI, 0.03 to 2.41), and a Gram-negative strain was involved in four of five cases.
Adverse Events
Three hundred ninety patients were assessable for adverse events. The overall incidence of adverse events was 6.4% in both treatment groups (12 of 187 in the combination and 13 of 203 in the monotherapy group). Nausea, vomiting, and diarrhea occurred in seven patients (3.7%) treated with tigecycline. Toxicities resulted in the discontinuation of treatment in three patients undergoing the combination and in five receiving monotherapy. 
DISCUSSION
The increase of relative proportion of bacteremias caused by gram negatives [6] [7] [8] and, at the same time the emergence of MDR microorganisms, 9-11 may be responsible for the inadequacy of monotherapy regimens, as well as of the classical ␤-lactam and aminoglycoside combination for the empiric treatment of febrile neutropenia in patients with cancer.
2,11-13 In this context, our study addresses two important issues: whether an association of antibiotics is better than monotherapy and whether tigecycline in combination can be used as empiric antibiotic therapy.
To our knowledge, this is the first multicenter, randomized, controlled, prospective trial powered to demonstrate that the combination of piperacillin/tazobactam with tigecycline is more effective than piperacillin/tazobactam alone for the empiric treatment of fever in persistently granulocytopenic patients with cancer. Combination regimen was associated with a significantly higher success rate compared with monotherapy in patients with bacteremia, as well as in patients with clinically documented infections. The use of the same antipseudomonal drug in the two arms of treatment and the uniform protocol guidelines for therapeutic decisions enabled us to attribute the differences in clinical responses exclusively to tigecycline.
Our study was open label. Unfortunately, the high cost of double dummy preparations and the difficulties to guarantee the use of an adequate masking technique in each participating center (because of the easily recognizable orange color of tigecycline solution), made the blinded design unaffordable for a spontaneous no-profit study.
Our methodology was aimed at reducing the possibility of bias in the interpretation of the results. Moreover, all the data recorded in the case report forms were entered into the computer system and assessed blinded for the assigned regimen by the data review committee.
In any case, the investigators' judgment does not seem to have been influenced by the unblinded design. In our study, both persistent or relapsing fever and progression of infection were considered and analyzed as reasons for failure burdened by subjectivity compared with other more objective and verifiable reasons. As shown in Table 3 , NOTE. Others factors included in the model but not associated with the failure of empiric antibiotic therapy were as follows: Sex: male v female; age (years): Յ 65 v Ͼ 65; performance status (WHO five points scale) Յ 2 v Ͼ 2; neutrophil count at onset of fever: Յ 100/mL v Ͼ 100/mL; and duration of neutropenia (days): Ͻ 10 v Ն 10.
Abbreviation: OR, odds ratio.
each reason for failure was equally distributed between the two treatment groups, and an objective and verifiable reason for failure represented approximately 60% of the total causes of failure in both treatment arms. Noteworthy, even if all the cases that failed because of a possible investigator's subjective judgment were reclassified as successes, the success rate of the combination was still higher than that of monotherapy (147 of 174 v 131 of 190; adr, 15%; 95% CI, 7% to 24%; P Ͻ .001). Tigecycline in combination with an antipseudomonal agent was effective regardless of the site of the infection. A substantial better response of the combination regimen was documented in bacteremias, in particular those caused by staphylococci and E coli. Because tigecycline achieves modest plasma concentrations, concerns were raised about its efficacy in the treatment of bacteremias and infections with organisms with a higher MIC. [26] [27] [28] [29] [30] However, no studies have been designed to evaluate the efficacy of tigecycline in bacteremias, although Chemaly 22 observed a good clinical response by using tigecycline for refractory bacteremias in patients with cancer.
In our study, the results of the combination regimen in bacteremias might have been influenced by an overall better in vitro activity of tigecycline against blood isolates compared with that of piperacillin/ tazobactam and also by the low incidence of bacteremias because of P aeruginosa, not covered by the tigecycline spectrum of activity. Noteworthy, in the combination arm, more than 30% of pathogens involved in single agent bacteremias were susceptible only to tigecycline, whereas tigecycline was the only active drug against the involved microorganisms in 60% of polymicrobial bacteremias. In patients with cancer, the reported rates of ESBL producer among E coli causing bacteremias account for up to 40%.
14,15,31,32 At the same time, mortality and the delay of effective therapy have been associated with ESBL production in Enterobacteriaceae bacteremia.
15,31, 32 The results of our study seems to indicate that in febrile, high-risk neutropenic patients (FhrNPs) the addition of tigecycline, active also against ESBL producers, could improve the adequacy of initial empiric monotherapy, and they also suggest that tigecycline in combination may contribute to reduce the overuse of carbapenems (overall, in our study, only the 27% of assessable population received a carbapenem) and anti-Gram-positive agents, as strongly recommended for the prevention of emergence of resistance.
33,34
This study was not powered to document an effect of the tigecycline combination in the reduction of mortality that in neutropenic patients with cancer may be also influenced by factors other than the empiric antibiotic therapy. The overall mortality rate evaluated at the end of the febrile episode was limited and similar in the two treatment groups. However, in patients receiving the combination therapy, we observed that a lower number of bacteremia-related early deaths occurred under the assigned antibiotic regimen (a Gram-negative was involved in four of five cases). Even if the difference was not statistically significant, it should be noted that in the combination arm only 12% of deaths because of bacteremia occurred within the first 72 hours from the start of empiric antibiotic therapy, compared with 50% in the monotherapy arm. This result is in line with studies revealing a better outcome and a higher overall survival rate in patients receiving initial adequate antibiotic therapy. 10, 14, 31, 32 The study confirms that in FhrNPs, tigecycline is safe and well tolerated.
In conclusion, the results of our study support the view 35 that a broad initial empirical combination regimen should be reserved to FhrNPs at high risk of developing infections because of MDR pathogens.
Because the majority of our patients was affected by acute leukemia, which was an independent factor for antibiotic treatment failure, and they had received intensive chemotherapy, the results of our study may not pertain to patients affected by other types of cancer, undergoing less intensive chemotherapy, and not receiving quinolones prophylaxis. We therefore believe that the combination containing tigecycline should be used as empiric therapy only for febrile neutropenic patients with acute leukemia in epidemiologic settings characterized by a high rate of MDR microorganisms, such as those observed in our study. The knowledge of local epidemiology is needed to drive the empiric antibiotic strategies together with a stringent enforcement of antibiotic stewardship programs. 
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